Back to top
more

Insulet (PODD)

(Delayed Data from NSDQ)

$203.51 USD

203.51
702,926

+1.05 (0.52%)

Updated Apr 8, 2026 04:00 PM ET

After-Market: $203.57 +0.06 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (169 out of 243)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Insulet (PODD) is a Top-Ranked Growth Stock: Should You Buy?

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Should You Continue to Hold Insulet Stock in Your Portfolio?

by Zacks Equity Research

PODD's Omnipod 5 momentum and strong growth outlook highlight upside, but macro pressures and rising competition could challenge its near-term performance.

Zacks Equity Research

Insulet (PODD) Down 8.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Medtronic Debuts MiniMed Go Smart MDI With Simplera Sensor in Europe

by Zacks Equity Research

MDT launches MiniMed Go Smart MDI with the Simplera sensor in Europe, advancing connected insulin care as the Diabetes unit's IPO plans progress.

Zacks Equity Research

PODD Stock Up on Q4 Earnings & Revenue Beat, Margins Rise

by Zacks Equity Research

Insulet jumps after Q4 EPS and revenue beat, margin expansion and record Omnipod growth power a strong 2025 finish and upbeat 2026 outlook.

Zacks Equity Research

Insulet (PODD) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

The headline numbers for Insulet (PODD) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Insulet (PODD) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Insulet (PODD) delivered earnings and revenue surprises of +4.87% and +2.15%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AtriCure (ATRC) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

AtriCure (ATRC) delivered earnings and revenue surprises of +400.00% and +0.01%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Exploring Analyst Estimates for Insulet (PODD) Q4 Earnings, Beyond Revenue and EPS

by Zacks Equity Research

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Insulet (PODD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.

Zacks Equity Research

Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.